Track Scholar Rock Holding Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Scholar Rock Holding Corporation SRRK Open Scholar Rock Holding Corporation in new tab

47.56 USD
EPS
-3.45
P/B
21.81
ROE
-138.94
Beta
0.71
Target Price
59.00 USD
Scholar Rock Holding Corporation logo

Scholar Rock Holding Corporation

🧾 Earnings Recap – Q3 2025

Scholar Rock faced a setback with its apitegromab application, receiving a complete response letter from the FDA, but remains optimistic about the drug's future approval for spinal muscular atrophy (SMA) thanks to strong clinical data and proactive measures.

  • The FDA's complete response letter cited manufacturing issues, specifically regarding the third-party fill/finish facility, rather than concerns over apitegromab's safety or efficacy.
  • Scholar Rock has initiated steps to secure an additional U.S.-based fill/finish facility to enhance production capacity and expedite future submissions.
  • The company successfully strengthened its balance sheet in Q3 2025, positioning itself for strategic investments to support long-term growth.
  • Regulatory meetings with the FDA were constructive, with plans for resubmission of the BLA anticipated in 2026.
  • The Phase II OPAL study for apitegromab in another rare neuromuscular disorder is underway, alongside advancing SRK-439 into clinical trials.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
EPS-3.45
Book Value2.26
Price to Book21.81
Debt/Equity74.52
% Insiders0.764%
Estimates
Forward P/E-21.79
Forward EPS-2.26
Target Mean Price59.00

DCF Valuation

Tweak assumptions to recompute fair value for Scholar Rock Holding Corporation (SRRK)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Scholar Rock Holding Corporation Logo Scholar Rock Holding Corporation Analysis (SRRK)

United States Health Care Official Website Stock

Is Scholar Rock Holding Corporation a good investment? Scholar Rock Holding Corporation (SRRK) is currently trading at 47.56 USD. Market analysts have a consensus price target of 59.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Scholar Rock Holding Corporation is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -2.26.

Investor FAQ

Does Scholar Rock Holding Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Scholar Rock Holding Corporation?

Scholar Rock Holding Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -3.45.

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) SRRK

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion